Eupraxia Pharmaceuticals Inc.
EPRXNASDAQHealthcare● Active
$6.09
+$0.14(+2.35%)
Market Cap$203893200
P/E Ratio—
52W High$9.32
52W Low$3.85
Eupraxia Pharmaceuticals Inc. (EPRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EPRX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.23
Est. -$0.22 · -4.5%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▼ Miss EPS
EPRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.25 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 12, 2026 | -$0.22 | -$0.23 | -4.5% | — | — | — |
| ▼ Q1 FY2026 | Mar 12, 2026 | -$0.16 | -$0.37 | -131.3% | — | — | — |
| ▲ Q4 FY2025 | Nov 4, 2025 | -$0.23 | -$0.19 | +17.4% | — | — | — |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.21 | -$0.26 | -23.8% | — | — | — |
| ▼ Q2 FY2025 | May 6, 2025 | -$0.19 | -$0.21 | -10.5% | — | — | — |
| ▼ Q1 FY2025 | Mar 20, 2025 | -$0.18 | -$0.21 | -16.7% | — | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.13 | -$0.17 | -30.1% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.25
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Miss
EPS Actual
-$0.23
EPS Est.
-$0.22
EPS Surpr.
-4.5%
Revenue
—
Q1 FY2026
Mar 12, 2026Miss
EPS Actual
-$0.37
EPS Est.
-$0.16
EPS Surpr.
-131.3%
Revenue
—
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
-$0.19
EPS Est.
-$0.23
EPS Surpr.
+17.4%
Revenue
—
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.26
EPS Est.
-$0.21
EPS Surpr.
-23.8%
Revenue
—
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$0.21
EPS Est.
-$0.19
EPS Surpr.
-10.5%
Revenue
—
Q1 FY2025
Mar 20, 2025Miss
EPS Actual
-$0.21
EPS Est.
-$0.18
EPS Surpr.
-16.7%
Revenue
—
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.17
EPS Est.
-$0.13
EPS Surpr.
-30.1%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-1.04 | $-1.04 | $-1.04 | 2 |
| Q3 FY2028 | $-0.80 | $-0.80 | $-0.80 | 2 |
| Q2 FY2028 | $-0.32 | $-0.32 | $-0.32 | 2 |
| Q1 FY2028 | $-0.33 | $-0.33 | $-0.33 | 2 |
| Q4 FY2027 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Q3 FY2027 | $-0.35 | $-0.35 | $-0.35 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 12, 2026 | -4.5% | $7.42 | $7.61 | +2.56% |
| ▼ Q1 FY2026 | Mar 12, 2026 | -131.3% | $7.69 | $7.50 | -2.47% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +17.4% | $6.09 | $5.45 | -10.51% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -23.8% | $5.33 | $5.37 | +0.75% |
| ▼ Q2 FY2025 | May 6, 2025 | -10.5% | $4.01 | $4.06 | +1.25% |
| ▼ Q1 FY2025 | Mar 20, 2025 | -16.7% | $4.02 | $3.91 | -2.74% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -30.1% | $3.11 | $3.16 | +1.61% |
| ▲ Q3 FY2024 | Aug 7, 2024 | -0.4% | $2.50 | $2.39 | -4.40% |
Q2 FY2026+2.56%
Report Date
May 12, 2026
EPS Beat/Miss
-4.5%
Price Before
$7.42
Price After
$7.61
Q1 FY2026-2.47%
Report Date
Mar 12, 2026
EPS Beat/Miss
-131.3%
Price Before
$7.69
Price After
$7.50
Q4 FY2025-10.51%
Report Date
Nov 4, 2025
EPS Beat/Miss
+17.4%
Price Before
$6.09
Price After
$5.45
Q3 FY2025+0.75%
Report Date
Aug 12, 2025
EPS Beat/Miss
-23.8%
Price Before
$5.33
Price After
$5.37
Q2 FY2025+1.25%
Report Date
May 6, 2025
EPS Beat/Miss
-10.5%
Price Before
$4.01
Price After
$4.06
Q1 FY2025-2.74%
Report Date
Mar 20, 2025
EPS Beat/Miss
-16.7%
Price Before
$4.02
Price After
$3.91
Q4 FY2024+1.61%
Report Date
Nov 7, 2024
EPS Beat/Miss
-30.1%
Price Before
$3.11
Price After
$3.16
Q3 FY2024-4.40%
Report Date
Aug 7, 2024
EPS Beat/Miss
-0.4%
Price Before
$2.50
Price After
$2.39
Avg Beat Reaction-7.46%
Avg Miss Reaction+0.16%
Beat Rate2 / 8 quarters
Largest Move-10.51% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EPRX ends December
Eupraxia Pharmaceuticals Inc. (EPRX) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.23 — missing the analyst consensus of $-0.22 by -4.5%. The next EPRX earnings date is expected around September 1, 2026.
Each quarter, investors track EPRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EPRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EPRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EPRX earnings · 5 questionsEupraxia Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. EPRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EPRX historically reports after market close (AMC).
EPRX earnings datewhen is EPRX earningsEPRX next earnings datewhen does EPRX report earningsEPRX earnings calendar
▸ Source: FMP · Eupraxia Pharmaceuticals Inc. SEC filings · US GAAP · Eupraxia Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026